Roivant Sciences Ltd.ROIVEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Vivek Ramaswamy | 9.75% | 81.5M | flat | 2024-02-14 |
| SB Investment Advisers | 9.10% | 73.0M | — | 2024-02-13 |
| QVT Financial LP | 8.28% | 66.7M | ▼ -5.69pp | 2024-03-07 |
| Viking Global Investors LP | 7.30% | 54.1M | ▼ -1.30pp | 2024-11-14 |
| FMR LLC | 6.64% | 49.1M | — | 2024-11-12 |
| BlackRock, Inc. | 5.70% | 42.0M | flat | 2024-11-08 |
| The Vanguard Group | 5.63% | 41.7M | flat | 2024-11-12 |
| Dexcel Pharma Technologies Ltd. | 0.58% | 4.7M | — | 2024-02-14 |
| Sumitomo Chemical Co., Ltd. | 0.00% | — | ▼ -8.86pp | 2024-04-02 |
Insider Transactions
Net 90d: −$226.08M · buys $0 / sells $226.08MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-20 | Jennifer Humes | Chief Accounting Officer | Grant | 29.2K | $0.00 | $0 |
| 2026-04-20 | Richard Pulik | CFO | Grant | 60.6K | $0.00 | $0 |
| 2026-04-20 | Eric Venker | President & Immunovant CEO | Option exercise | 200.0K | $3.85 | $770.0K |
| 2026-04-20 | Eric Venker | President & Immunovant CEO | Sell (open market) | 200.0K | $29.59 | $5.92M |
| 2026-04-17 | Ilan Oren | Director | Grant | 896 | $0.00 | $0 |
| 2026-04-17 | MOMTAZEE JAMES C | Director | Grant | 469 | $0.00 | $0 |
| 2026-04-17 | Epperly Melissa B, | Director | Grant | 670 | $0.00 | $0 |
| 2026-04-16 | Matthew Gline | CEO | Sell (open market) | 289.8K | $29.16 | $8.45M |
| 2026-04-08 | Jennifer Humes | Chief Accounting Officer | Sell (open market) | 13.5K | $28.37 | $384.1K |
| 2026-03-30 | Mayukh Sukhatme | President & CIO | Option exercise | 58.4K | — | — |
1–10 of 42
Page 1 / 5